Mr. Clark, you mentioned that one of the biggest barriers or obstacles to would-be importing countries accessing this program is money. I take it that as a least developed country you have decisions to make, and sometimes you may find that you don't have the capital to invest in medicines purchased from overseas. CIDA does have the cash, and Foreign Affairs has a role to play as well. We do have a $250 million two-year commitment to the global fund. I'd like to hear from each player at the table on this. Does the concept of CIDA embarking upon pilot projects in the variety I've described--consistent with CIDA's normal delivery mechanisms--make sense to provide Canada a baseline of data and a track record as to whether or not this enabling legislation works or whether this is a systemic process problem we are engaged in?
Mr. Lee, would you be able to kick off the answers as to whether or not you would find it helpful to have a pilot project to study?